BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013; 19(41): 6969-6978 [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969]
URL: https://www.wjgnet.com/1007-9327/full/v19/i41/6969.htm
(514) (461) (0) (0) (16586) (228)
Number Citing Articles
1
Eleonora Scorletti, Rotonya M. Carr. A new perspective on NAFLD: Focusing on lipid droplets. Journal of Hepatology 2022; 76(4) doi: 10.1016/j.jhep.2021.11.009
2
Haiying Zhang, Li Xue, Lizhen Chen, Shunshun Jiang, Yongning Xin, Shiying Xuan. A Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis C. Hepatitis Monthly 2015; 15(11) doi: 10.5812/hepatmon.31987
3
Reem Al-Qarni, Muhammad Iqbal, Maram Al-Otaibi, Faisal Al-Saif, Assim A. Alfadda, Hisham Alkhalidi, Fahad Bamehriz, Mazen Hassanain. Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine 2020; 99(36) doi: 10.1097/MD.0000000000021463
4
Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Alimentary Pharmacology & Therapeutics 2023; 57(1) doi: 10.1111/apt.17292
5
Samantha G. Tilson, Carola M. Morell, An‐Sofie Lenaerts, Seung Bum Park, Zongyi Hu, Benjamin Jenkins, Albert Koulman, T. Jake Liang, Ludovic Vallier. Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells. Hepatology 2021; 74(6) doi: 10.1002/hep.32063
6
Raffaela Rametta, Massimiliano Ruscica, Paola Dongiovanni, Chiara Macchi, Anna L. Fracanzani, Liliana Steffani, Silvia Fargion, Paolo Magni, Luca Valenti. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin‐A independently of insulin resistance. European Journal of Clinical Investigation 2014; 44(7) doi: 10.1111/eci.12280
7
Zongsheng Huang, Xianwen Guo, Guo Zhang, Liexin Liang, Bing Nong. Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects. The International Journal of Biological Markers 2019; 34(2) doi: 10.1177/1724600818812471
8
Piero Pingitore, Paola Dongiovanni, Benedetta Maria Motta, Marica Meroni, Saverio Massimo Lepore, Rosellina Margherita Mancina, Serena Pelusi, Cristina Russo, Andrea Caddeo, Giorgio Rossi, Tiziana Montalcini, Arturo Pujia, Olov Wiklund, Luca Valenti, Stefano Romeo. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Human Molecular Genetics 2016;  doi: 10.1093/hmg/ddw341
9
Jian-Hua Shen, Yi-Ling Li, Dan Li, Ning-Ning Wang, Lei Jing, Yu-Hong Huang. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. Journal of Lipid Research 2015; 56(1) doi: 10.1194/jlr.M048777
10
Anita Arslanow, Caroline S. Stokes, Susanne N. Weber, Frank Grünhage, Frank Lammert, Marcin Krawczyk. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). Liver International 2016; 36(3) doi: 10.1111/liv.12937
11
Yen‐Po Lin, Yu‐Chieh Tsai, Mu Jung Tsai, Pao‐Yuan Huang, Chien‐Hung Chen, Chih‐Chien Yao, Seng‐Kee Chuah, Yuan‐Hung Kuo, Wei‐Chen Tai, Wei‐Shiung Lian, Hsin‐Wei Fang, Tsung‐Hui Hu, Ming‐Chao Tsai. Effect of gut microbiota and PNPLA3 polymorphisms on nonalcoholic fatty liver disease in lean and obese individuals. Advances in Digestive Medicine 2024; 11(3) doi: 10.1002/aid2.13367
12
Luigi Boccuto, Ludovico Abenavoli, Lauren Cascio, Sujata Srikanth, Barbara DuPont, Andrew R. Mitz, Roger Curtis Rogers, Katy Phelan. Variability in Phelan‐McDermid syndrome: The impact of the PNPLA3 p.I148M polymorphism. Clinical Genetics 2018; 94(6) doi: 10.1111/cge.13451
13
Stefano Romeo, Luca Valenti. Regulation of retinol‐binding protein 4 and retinol metabolism in fatty liver disease. Hepatology 2016; 64(5) doi: 10.1002/hep.28722
14
Roberta Fares, Salvatore Petta, Rosa Lombardi, Stefania Grimaudo, Paola Dongiovanni, Rosaria Pipitone, Raffaela Rametta, Anna Ludovica Fracanzani, Enrico Mozzi, Antonio Craxì, Silvia Fargion, Giorgio Sesti, Luca Valenti. The UCP2 ‐866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International 2015; 35(5) doi: 10.1111/liv.12707
15
Kentaro Oniki, Junji Saruwatari, Tomoko Izuka, Ayami Kajiwara, Kazunori Morita, Misaki Sakata, Koji Otake, Yasuhiro Ogata, Kazuko Nakagawa, Silvia C. Sookoian. Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects. PLOS ONE 2015; 10(7) doi: 10.1371/journal.pone.0132640
16
Ciro Celsa, Grazia Pennisi, Adele Tulone, Giacinta Ciancimino, Marco Vaccaro, Fabiana Pecorella, Gabriele Di Maria, Marco Enea, Giovanni Targher, Luca Valenti, Stefano Romeo, Calogero Cammà, Salvatore Petta. PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: A meta-analysis of observational studies. JHEP Reports 2026; 8(8) doi: 10.1016/j.jhepr.2026.101918
17
Stefano Romeo, Luca Valenti. Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics. Liver International 2025; 45(9) doi: 10.1111/liv.70240
18
Ines Volkert, Malin Fromme, Carolin Schneider, Lena Candels, Cecilia Lindhauer, Huan Su, Katrine Thorhauge, Monica Pons, Mohamed Ramadan Mohamed, Kai Markus Schneider, Pavel Strnad, Christian Trautwein. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression. Hepatology 2024; 79(4) doi: 10.1097/HEP.0000000000000574
19
Alireza Ramandi, Anna‐Mae Diehl, Arun J. Sanyal, Ype P. de Jong. Experimental Models to Investigate PNPLA3 in Liver Steatosis. Liver International 2025; 45(5) doi: 10.1111/liv.70091
20
R.B. Prussick, L. Miele. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. British Journal of Dermatology 2018; 179(1) doi: 10.1111/bjd.16239
21
Vittoria Manilla, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani. Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer. Nutrients 2023; 15(11) doi: 10.3390/nu15112521
22
. 2021;  doi: 10.70675/59e48d7ezf6c4z4d80za13czb4e84b35e3dc
23
Guido Alessandro Baselli, Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Serena Pelusi, Marco Maggioni, Sara Badiali, Piero Pingitore, Samantha Maurotti, Tiziana Montalcini, Alice Emma Taliento, Daniele Prati, Giorgio Rossi, Anna Ludovica Fracanzani, Rosellina Margherita Mancina, Stefano Romeo, Luca Valenti. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut 2020; 69(10) doi: 10.1136/gutjnl-2019-319226
24
Mohammed Eslam, Luca Valenti, Stefano Romeo. Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology 2018; 68(2) doi: 10.1016/j.jhep.2017.09.003
25
Nina L. Gluchowski, Michel Becuwe, Tobias C. Walther, Robert V. Farese. Lipid droplets and liver disease: from basic biology to clinical implications. Nature Reviews Gastroenterology & Hepatology 2017; 14(6) doi: 10.1038/nrgastro.2017.32
26
Anna Viitasalo, Mustafa Atalay, Jussi Pihlajamäki, Jarmo Jääskeläinen, Ayhan Korkmaz, Dorota Kaminska, Virpi Lindi, Timo A. Lakka. The 148 M allele of the PNPLA3 is associated with plasma irisin levels in a population sample of Caucasian children: The PANIC Study. Metabolism 2015; 64(7) doi: 10.1016/j.metabol.2015.01.010
27
Jinsil Kim, Hyuk Gyoon Lee, Minwook Shin. Programmable RNA Editing via Adenosine Deaminase Acting on RNA Enzymes: Current Advances and Clinical Potential. Nucleic Acid Therapeutics 2026; 36(2) doi: 10.1177/21593337251415115
28
Alessandro Mantovani, Stefano Ballestri, Amedeo Lonardo, Giovanni Targher. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences 2016; 61(5) doi: 10.1007/s10620-016-4040-6
29
Marina Kawaguchi-Suzuki, Kenneth Cusi, Fernando Bril, Yan Gong, Taimour Langaee, Reginald F. Frye. A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00752
30
Mihaela-Andreea Podeanu, Raluca Elena Sandu, Bianca Ștefănița Vintilescu, Claudiu Marinel Ionele, Ion Rogoveanu, Ioana Streață, Carmen Elena Niculescu, Dan Nicolae Florescu, Sergiu-Marian Cazacu, Ștefania Cornelia Andrei, Adina Maria Barbu, Mioara Desdemona Stepan. Ferritin and Liver Steatosis in Children: Interactions Between Metabolic Clustering and PNPLA3 Variants. International Journal of Molecular Sciences 2026; 27(7) doi: 10.3390/ijms27073044
31
Marcin Krawczyk, Raúl Jiménez-Agüero, José M. Alustiza, José I. Emparanza, María J. Perugorria, Luis Bujanda, Frank Lammert, Jesús M. Banales. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases 2016; 12(10) doi: 10.1016/j.soard.2016.06.004
32
Rosa Lombardi, Salvatore Petta, Giuseppina Pisano, Paola Dongiovanni, Luca Rinaldi, Luigi Elio Adinolfi, Carlo Acierno, Luca Valenti, Roberta Boemi, Federica Spatola, Antonio Craxì, Silvia Fargion, Anna Ludovica Fracanzani. FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology 2020; 18(2) doi: 10.1016/j.cgh.2018.11.011
33
Yongqiang Ma, Guangshun Chen, Junfang Yi, Qiang Li, Zhi Tan, Wenling Fan, Xiaohua Luo, Zhiyong He, Zhongzhou Si, Jiequn Li. IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.895593
34
Cristiana Bianco, Elia Casirati, Francesco Malvestiti, Luca Valenti. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Reports 2021; 3(3) doi: 10.1016/j.jhepr.2021.100284
35
Nathan L Meyers, Krystal A Fontaine, G Renuka Kumar, Melanie Ott. Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection. Current Opinion in Cell Biology 2016; 41 doi: 10.1016/j.ceb.2016.05.003
36
Marica Meroni, Miriam Longo, Giada Tria, Paola Dongiovanni. Genetics Is of the Essence to Face NAFLD. Biomedicines 2021; 9(10) doi: 10.3390/biomedicines9101359
37
Anthony J. Demetris, Marta I. Minervini, Michael A. Nalesnik, Parmjeet Randhawa, Eizaburo Sasatomi. Transplantation of the Liver. 2015;  doi: 10.1016/B978-1-4557-0268-8.00084-1
38
Na Li, Xiaodan Li, Yifu Ding, Xiao Liu, Karin Diggle, Tatiana Kisseleva, David A. Brenner. SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies. Biomedicines 2023; 11(12) doi: 10.3390/biomedicines11123280
39
Maria A. Burza, Rocco Spagnuolo, Tiziana Montalcini, Patrizia Doldo, Arturo Pujia, Stefano Romeo. Effect of Excess Body Weight on the Genetic Susceptibility to Cancer. Journal of Clinical Gastroenterology 2014; 48(Supplement 1) doi: 10.1097/MCG.0000000000000237
40
Hiroyasu Sakai, Yohei Shirakami, Masahito Shimizu. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World Journal of Gastroenterology 2016; 22(1): 394-406 doi: 10.3748/wjg.v22.i1.394
41
Rosa Lombardi, Silvia Fargion, Anna Ludovica Fracanzani. Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. Digestive and Liver Disease 2019; 51(9) doi: 10.1016/j.dld.2019.05.015
42
Santiago Iturbe-Rey, Claudia Maccali, Marco Arrese, Patricia Aspichueta, Claudia P. Oliveira, Rui E. Castro, Ainhoa Lapitz, Laura Izquierdo-Sanchez, Luis Bujanda, Maria J. Perugorria, Jesus M. Banales, Pedro M. Rodrigues. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis 2025; 400 doi: 10.1016/j.atherosclerosis.2024.119053
43
Mengying Xia, Mahboubeh Varmazyad, Iris Pla-Palacín, Dillon C. Gavlock, Richard DeBiasio, Gregory LaRocca, Celeste Reese, Rodrigo M. Florentino, Lanuza A. P. Faccioli, Jacquelyn A. Brown, Lawrence A. Vernetti, Mark Schurdak, Andrew M. Stern, Albert Gough, Jaideep Behari, Alejandro Soto-Gutierrez, D. Lansing Taylor, Mark T. Miedel. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1423936
44
Omnia Aly, Hanan Hassan Zaki, Mohamed R. Herzalla, Ahmed Fathy, Nermin Raafat, Mohamed M. Hafez, Nadia M Hamdy. Gene polymorphisms of Patatin-like phospholipase domain containing 3 (PNPLA3), adiponectin, leptin in diabetic obese patients. PLOS ONE 2020; 15(6) doi: 10.1371/journal.pone.0234465
45
Alessandra Cazzaniga, Silvia Frigo, Alessandro Cherubini, Eniada Rrapaj, Luca Valenti. Autophagy in MASLD: A Metabolic and Precision Medicine Perspective. Liver International 2026; 46(9) doi: 10.1111/liv.70816
46
Jaejun Lee, Dong Yeop Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Pil Soo Sung. PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients. Journal of Liver Cancer 2026; 26(1) doi: 10.17998/jlc.2025.11.16
47
Angeliki M Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P Mikhailidis, George Jacob, Christos S Mantzoros. MASLD and the cardiovascular-kidney-liver-metabolic syndrome. Endocrine Reviews 2026;  doi: 10.1210/endrev/bnag023
48
Anna Viitasalo, Jussi Pihlajamäki, Jussi Paananen, Mustafa Atalay, Virpi Lindi, Timo A Lakka. Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study. Pediatric Research 2016; 79(5) doi: 10.1038/pr.2016.3
49
Anna Di Sessa, Giuseppina Rosaria Umano, Grazia Cirillo, Angela Del Prete, Roberta Iacomino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice. The Membrane‐bound O‐Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition 2018; 67(1) doi: 10.1097/MPG.0000000000001979
50
Edgar A. Villavicencio, Adriana Maldonado, Rebecca M. Crocker, Yue Guan, Chris Stallman, David O. Garcia. Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. Frontiers in Public Health 2023; 10 doi: 10.3389/fpubh.2022.1090101
51
Sven M. Francque. Towards precision medicine in non-alcoholic fatty liver disease. Reviews in Endocrine and Metabolic Disorders 2023; 24(5) doi: 10.1007/s11154-023-09820-6
52
Xiao Yang, Frank J. Gonzalez, Min Huang, Huichang Bi. Nuclear receptors and non-alcoholic fatty liver disease: An update. Liver Research 2020; 4(2) doi: 10.1016/j.livres.2020.03.001
53
Wenke Jonas, Annette Schürmann. Genetic and epigenetic factors determining NAFLD risk. Molecular Metabolism 2021; 50 doi: 10.1016/j.molmet.2020.101111
54
Valerio Nobili, Anna Alisi, Luca Valenti, Luca Miele, Ariel E. Feldstein, Naim Alkhouri. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology & Hepatology 2019; 16(9) doi: 10.1038/s41575-019-0169-z
55
Cheng Peng, Alastair G. Stewart, Owen L. Woodman, Rebecca H. Ritchie, Cheng Xue Qin. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.603926
56
Dina S. Ata, Mohy A.E. Awad, Manal A.E. Eid, Khaled I. ElShafey, Ola A. Taha. PNPLA3/adiponutrin I148M gene variant in nonalcoholic fatty liver disease in Egyptian children and adolescents. Alexandria Journal of Pediatrics 2021; 34(3) doi: 10.4103/1687-9945.337830
57
Miriam Longo, Erika Paolini, Marica Meroni, Paola Dongiovanni. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. International Journal of Molecular Sciences 2021; 22(8) doi: 10.3390/ijms22084173
58
Mark A. Febbraio, Saskia Reibe, Shabnam Shalapour, Geraldine J. Ooi, Matthew J. Watt, Michael Karin. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metabolism 2019; 29(1) doi: 10.1016/j.cmet.2018.10.012
59
Dilum Ekanayake, Clinton Roddick, Lawrie W. Powell. Recent advances in hemochromatosis: a 2015 update. Hepatology International 2015; 9(2) doi: 10.1007/s12072-015-9608-2
60
O. V. Smirnova, O. L. Moskalenko, E. V. Kasparov, I. E. Kasparova. Genetic predictors and pathophysiological features of non-alcoholic fat liver disease. Meditsinskiy sovet = Medical Council 2021; (15) doi: 10.21518/2079-701X-2021-15-78-87
61
Verena Wieser, Timon E. Adolph, Barbara Enrich, Patrizia Moser, Alexander R. Moschen, Herbert Tilg. Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. Liver International 2017; 37(2) doi: 10.1111/liv.13222
62
Sofía Montemayor, Silvia García, Margalida Monserrat-Mesquida, Josep A. Tur, Cristina Bouzas. Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review. Nutrients 2023; 15(18) doi: 10.3390/nu15183987
63
Viktoriia Iakovleva, Ype P. de Jong. Gene-based therapies for steatotic liver disease. Molecular Therapy 2025; 33(6) doi: 10.1016/j.ymthe.2025.04.024
64
Tsunehiro Ochi, Kensuke Munekage, Masafumi Ono, Takuma Higuchi, Masayuki Tsuda, Yoshihiro Hayashi, Nobuto Okamoto, Katsumi Toda, Shuji Sakamoto, Jude A. Oben, Toshiji Saibara. Patatin-like phospholipase domain-containing protein 3 is involved in hepatic fatty acid and triglyceride metabolism through X-box binding protein 1 and modulation of endoplasmic reticulum stress in mice. Hepatology Research 2016; 46(6) doi: 10.1111/hepr.12587
65
D. S. Kozlov, S. Rodimova, P. Filatov, A. Mozherov, P. S. Timashev, M. V. Zyuzin, D. S. Kuznetsova. Genomic medicine in hepatology: mechanisms and liver treatment strategies. Molecular Medicine 2025; 31(1) doi: 10.1186/s10020-025-01358-4
66
Emmi Suomela, Mervi Oikonen, Niina Pitkänen, Ari Ahola-Olli, Johanna Virtanen, Riitta Parkkola, Eero Jokinen, Tomi Laitinen, Nina Hutri-Kähönen, Mika Kähönen, Terho Lehtimäki, Leena Taittonen, Päivi Tossavainen, Antti Jula, Britt-Marie Loo, Vera Mikkilä, Risto Telama, Jorma S.A. Viikari, Markus Juonala, Olli T. Raitakari. Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study. Journal of Hepatology 2016; 65(4) doi: 10.1016/j.jhep.2016.05.020
67
Alessandra Caligiuri, Alessandra Gentilini, Fabio Marra. Molecular Pathogenesis of NASH. International Journal of Molecular Sciences 2016; 17(9) doi: 10.3390/ijms17091575
68
Alexander J. Kovalic, Pratik Banerjee, Quynh T. Tran, Ashwani K. Singal, Sanjaya K. Satapathy. Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology 2018; 8(4) doi: 10.1016/j.jceh.2018.04.001
69
Huan Su, Madhuri Haque, Svea Becker, Karolina Edlund, Julia Duda, Qingbi Wang, Johanna Reißing, Hanns‐Ulrich Marschall, Lena S. Candels, Mohamed Mohamed, Wilhelm Sjöland, Lijun Liao, Stephan A. Drexler, Till Strowig, Jörg Rahnenführer, Jan G. Hengstler, Maximilian Hatting, Christian Trautwein. Long‐term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals. Liver International 2023; 43(8) doi: 10.1111/liv.15587
70
Shuixian Du, Jianhong Yin, Kezhen Hu, Yongning Xin. The Proportion of PNPLA3 rs738409 GG Homozygous in Different Populations and Its Impact on Fibrosis Progression in Biopsy-Proven NAFLD Patients: Meta-Analysis and Systematic Review. Hepatitis Monthly 2025; 25(1) doi: 10.5812/hepatmon-160524
71
Elias Björnson, Bani Mukhopadhyay, Anna Asplund, Nusa Pristovsek, Resat Cinar, Stefano Romeo, Mathias Uhlen, George Kunos, Jens Nielsen, Adil Mardinoglu. Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. Cell Reports 2015; 13(9) doi: 10.1016/j.celrep.2015.10.045
72
Stella De Nicola, Paola Dongiovanni, Alessio Aghemo, Cristina Cheroni, Roberta D'Ambrosio, Michele Pedrazzini, Francesco Marabita, Lorena Donnici, Marco Maggioni, Silvia Fargion, Massimo Colombo, Raffaele De Francesco, Luca Valenti, Matias A. Avila. Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C. PLoS ONE 2014; 9(8) doi: 10.1371/journal.pone.0106022
73
Ahmad Al-Mrabeh, Sviatlana V. Zhyzhneuskaya, Carl Peters, Alison C. Barnes, Shaden Melhem, Aaron Jesuthasan, Benjamin Aribisala, Kieren G. Hollingsworth, Georg Lietz, John C. Mathers, Naveed Sattar, Michael E.J. Lean, Roy Taylor. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. Cell Metabolism 2020; 31(2) doi: 10.1016/j.cmet.2019.11.018
74
R. Liebe, F. Lammert, M. Krawczyk. Metabolism and Pathophysiology of Bariatric Surgery. 2017;  doi: 10.1016/B978-0-12-804011-9.00051-0
75
Eric Trépo, Luca Valenti. Update on NAFLD genetics: From new variants to the clinic. Journal of Hepatology 2020; 72(6) doi: 10.1016/j.jhep.2020.02.020
76
Ahmad Al-Mrabeh. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us?. Cardiovascular Endocrinology & Metabolism 2020; 9(4) doi: 10.1097/XCE.0000000000000201
77
Benedetta Donati, Paola Dongiovanni, Stefano Romeo, Marica Meroni, Misti McCain, Luca Miele, Salvatore Petta, Silvia Maier, Chiara Rosso, Laura De Luca, Ester Vanni, Stefania Grimaudo, Renato Romagnoli, Fabio Colli, Flaminia Ferri, Rosellina Margherita Mancina, Paula Iruzubieta, Antonio Craxi, Anna Ludovica Fracanzani, Antonio Grieco, Stefano Ginanni Corradini, Alessio Aghemo, Massimo Colombo, Giorgio Soardo, Elisabetta Bugianesi, Helen Reeves, Quentin M. Anstee, Silvia Fargion, Luca Valenti. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-04991-0
78
Sunday Amos Onikanni, Bashir Lawal, Oluwafemi Shittu Bakare, Basiru Olaitan Ajiboye, Oluwafemi Adeleke Ojo, Abdullah Farasani, Saeed M Kabrah, Gaber El-Saber Batiha, Carlos Adam Conte-Junior. Cancer of the Liver and its Relationship with Diabetes mellitus. Technology in Cancer Research & Treatment 2022; 21 doi: 10.1177/15330338221119743
79
Ana Cecilia Pontoriero, Julieta Trinks, María Laura Hulaniuk, Mariela Caputo, Lisandro Fortuny, Leandro Burgos Pratx, Analía Frías, Oscar Torres, Félix Nuñez, Adrián Gadano, Pablo Argibay, Daniel Corach, Diego Flichman. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genetics 2015; 16(1) doi: 10.1186/s12863-015-0255-3
80
Amal M.H. Mackawy, Mohamed E.H. Badawi, Ola Megahed. Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients. Egyptian Journal of Medical Human Genetics 2015; 16(4) doi: 10.1016/j.ejmhg.2015.06.001
81
Rosa Lombardi, Alessandro Mantovani, Annalisa Cespiati, Paolo Francione, Gabriele Maffi, Elena Del Zanna, Claudio Maffeis, Antonio Colecchia, Nicola Passigato, Alberto Ferrarese, Caterina Daniela Cusumanu, Rosanna Villani, Emanuela Orsi, Valeria Grancini, Lorena Airaghi, Daniela Bignamini, Gaetano Serviddio, Giovanni Targher, Paola Dongiovanni, Silvia Fargion, Anna Ludovica Fracanzani. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. Digestive and Liver Disease 2024; 56(4) doi: 10.1016/j.dld.2023.09.023
82
Agostino Di Ciaula, Leonilde Bonfrate, Marcin Krawczyk, Gema Frühbeck, Piero Portincasa. Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. International Journal of Molecular Sciences 2022; 23(5) doi: 10.3390/ijms23052636
83
Yanfang Zhang, Tongsheng Guo, Funing Yang, Yuanli Mao, Liubing Li, Chenxi Liu, Qiang Sun, Yongzhe Li, Jing Huang. Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males. Hepatology International 2018; 12(5) doi: 10.1007/s12072-018-9889-3
84
Susanne Schuster, Daniel Cabrera, Marco Arrese, Ariel E. Feldstein. Triggering and resolution of inflammation in NASH. Nature Reviews Gastroenterology & Hepatology 2018; 15(6) doi: 10.1038/s41575-018-0009-6
85
Paloma Sangro, Manuel de la Torre Aláez, Bruno Sangro, Delia D’Avola. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. Journal of Physiology and Biochemistry 2023; 79(4) doi: 10.1007/s13105-023-00954-4
86
Yan Zhao, Wenli Zhao, Jingchao Ma, Maeda Toshiyoshi, Ye Zhao. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies. Medicine 2023; 102(10) doi: 10.1097/MD.0000000000033110
87
Rosa Lombardi, Federica Iuculano, Giada Pallini, Silvia Fargion, Anna Ludovica Fracanzani. Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences 2020; 21(22) doi: 10.3390/ijms21228761
88
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto. Screening strategy for non-alcoholic fatty liver disease. Clinical and Molecular Hepatology 2023; 29(Suppl) doi: 10.3350/cmh.2022.0336
89
Paola Dongiovanni, Erika Paolini, Alberto Corsini, Cesare R. Sirtori, Massimiliano Ruscica. Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation 2021; 51(7) doi: 10.1111/eci.13519
90
Amedeo Lonardo, Fabio Nascimbeni, Giovanni Targher, Mauro Bernardi, Ferruccio Bonino, Elisabetta Bugianesi, Alessandro Casini, Amalia Gastaldelli, Giulio Marchesini, Fabio Marra, Luca Miele, Filomena Morisco, Salvatore Petta, Fabio Piscaglia, Gianluca Svegliati-Baroni, Luca Valenti, Stefano Bellentani. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease 2017; 49(5) doi: 10.1016/j.dld.2017.01.147
91
Björn Carlsson, Daniel Lindén, Gabriella Brolén, Mathias Liljeblad, Mikael Bjursell, Stefano Romeo, Rohit Loomba. Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2020; 51(12) doi: 10.1111/apt.15738
92
Paola Dongiovanni, Luca Valenti. Genetics of nonalcoholic fatty liver disease. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2015.08.018
93
Cristina B. Guzman, Suman Duvvuru, Anthony Akkari, Pallav Bhatnagar, Chakib Battioui, Wendra Foster, Xiaotian Michelle Zhang, Sudha S. Shankar, Mark A. Deeg, Naga Chalasani, Thomas A. Hardy, Christof M. Kazda, Sreekumar G. Pillai. Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist. Hepatology Communications 2018; 2(5) doi: 10.1002/hep4.1171
94
Zitao Liu, Haoyuan Peng, Pengfei Liu, Feiyi Duan, Yutian Yang, Pengkun Li, Zhihao Li, Jiaoyan Wu, Jiayi Chang, Dandan Shang, Qiwen Tian, Jiawei Zhang, Yucheng Xie, Zhenzhen Liu, Yang An. Deciphering significances of autophagy in the development and metabolism of adipose tissue. Experimental Cell Research 2025; 446(2) doi: 10.1016/j.yexcr.2025.114478
95
Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, Jannis Kountouras, Panagiotis Katsinelos. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017; 71 doi: 10.1016/j.metabol.2017.03.013
96
Nigar Anjuman Khurram. Practical Liver Pathology. Practical Anatomic Pathology 2025;  doi: 10.1007/978-3-031-97506-6_15
97
Onni Niemelä. Advances In Clinical Chemistry. Advances in Clinical Chemistry 2023; 116 doi: 10.1016/bs.acc.2023.05.002
98
Jérôme Boursier, Anna Mae Diehl. Patatin‐like phospholipase domain‐containing protein 3 and Liver Disease: Opportunities to Unravel Mechanisms Underlying Statistical Associations. Hepatology 2015; 61(1) doi: 10.1002/hep.27445
99
Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Luca Valenti. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?. Expert Review of Gastroenterology & Hepatology 2016; 10(2) doi: 10.1586/17474124.2016.1110018
100
Carmen Fierbinteanu-Braticevici, Crina Sinescu, Alexandru Moldoveanu, Ana Petrisor, Sorina Diaconu, Dragos Cretoiu, Bogdan Braticevici. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biology and Toxicology 2017; 33(1) doi: 10.1007/s10565-016-9361-x
101
Martijn R. Molenaar, Louis C. Penning, J. Bernd Helms. Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease. Cells 2020; 9(10) doi: 10.3390/cells9102244
102
Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti, Ariel E. Feldstein. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Seminars in Liver Disease 2021; 41(04) doi: 10.1055/s-0041-1730927
103
Silvia Sookoian, Carlos J. Pirola, Luca Valenti, Nicholas O. Davidson. Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology 2020; 72(1) doi: 10.1002/hep.31229
104
Sandra Steensels, Jixuan Qiao, Baran A. Ersoy. Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease. Metabolites 2020; 10(7) doi: 10.3390/metabo10070283
105
Ziming Zheng, Yumei Huang, Jijuan Zhang, Jinchi Xie, An Pan, Yunfei Liao, Yu Zhang. Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. Annals of Hepatology 2026; 31(1) doi: 10.1016/j.aohep.2025.102136
106
Sylwia Ziolkowska, Agata Binienda, Maciej Jabłkowski, Janusz Szemraj, Piotr Czarny. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2021; 22(20) doi: 10.3390/ijms222011128
107
Alejandro Arreola Cruz, Juan Carlos Navarro Hernández, Laura Estela Cisneros Garza, Antonio Miranda Duarte, Viviana Leticia Mata Tijerina, Magda Elizabeth Hernández Garcia, Katia Peñuelas-Urquides, Laura Adiene González-Escalante, Mario Bermúdez de León, Beatriz Silva Ramirez. Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 Genetic Variants to Hepatocellular Carcinoma Development in Mexican Patients. International Journal of Molecular Sciences 2025; 26(15) doi: 10.3390/ijms26157409
108
Sven Francque, Vlad Ratziu. Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2023; 27(2) doi: 10.1016/j.cld.2023.01.010
109
Haofei Hu, Changchun Cao, Yong Han, Yongcheng He. Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.984241
110
Joseph L. Dempsey, George N. Ioannou, Rotonya M. Carr. Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases. Seminars in Liver Disease 2023; 43(04) doi: 10.1055/a-2186-3557
111
Paola Dongiovanni, Salvatore Petta, Ville Mannisto, Rosellina Margherita Mancina, Rosaria Pipitone, Vesa Karja, Marco Maggioni, Pirjo Kakela, Olov Wiklund, Enrico Mozzi, Stefania Grimaudo, Dorota Kaminska, Raffaela Rametta, Antonio Craxi, Silvia Fargion, Valerio Nobili, Stefano Romeo, Jussi Pihlajamaki, Luca Valenti. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015; 63(3) doi: 10.1016/j.jhep.2015.05.006
112
Kh. A. Kurtanov, L. A. Sydykova, N. I. Pavlova, N. P. Filippova, V. V. Dodokhov, G. A. Apsolikhova, N. A. Solov'eva, A. T. D'yakonova, L. M. Neustroeva, M. A. Varlamova, N. V. Borisova. Polymorphism of the adiponutrin gene (PNPLA3) in the indigenous inhabitants of the Republic of Sakha (Yakutia) with type 2 diabetes mellitus. Almanac of Clinical Medicine 2018; 46(3) doi: 10.18786/2072-0505-2018-46-3-258-263
113
Erika Paolini, Miriam Longo, Marica Meroni, Paola Podini, Marco Maggioni, Angelo Quattrini, Anna Ludovica Fracanzani, Paola Dongiovanni. A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD. Antioxidants 2025; 14(6) doi: 10.3390/antiox14060618
114
Nwe Ni Than, Philip N. Newsome. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239(1) doi: 10.1016/j.atherosclerosis.2015.01.001
115
Ruizhe Ren, Xiao Liang, Xiyang Wei. Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options. Molecular Biomedicine 2026; 7(1) doi: 10.1186/s43556-026-00486-5
116
Erika Paolini, Marica Meroni, Miriam Longo, Sara Badiali, Marco Maggioni, Anna Ludovica Fracanzani, Paola Dongiovanni. The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones. International Journal of Molecular Sciences 2026; 27(3) doi: 10.3390/ijms27031601
117
Manoj Amrutkar, Urszula Chursa, Matthias Kern, Esther Nuñez‐Durán, Marcus Ståhlman, Silva Sütt, Jan Borén, Bengt R. Johansson, Hanns‐Ulrich Marschall, Matthias Blüher, Margit Mahlapuu. STK25 is a critical determinant in nonalcoholic steatohepatitis. The FASEB Journal 2016; 30(10) doi: 10.1096/fj.201600562R
118
A.‐J. Chamorro, J.‐L. Torres, J.‐A. Mirón‐Canelo, R. González‐Sarmiento, F.‐J. Laso, M. Marcos. Systematic review with meta‐analysis: the I148M variant of patatin‐like phospholipase domain‐containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Alimentary Pharmacology & Therapeutics 2014; 40(6) doi: 10.1111/apt.12890
119
Michael Zimmer, Pradeep Bista, Ericka L. Benson, Diana Y. Lee, Feng Liu, Dominic Picarella, Rick B. Vega, Chi B. Vu, Maisy Yeager, Min Ding, Guosheng Liang, Jay D. Horton, Robert Kleemann, Teake Kooistra, Martine C. Morrison, Peter Y. Wielinga, Jill C. Milne, Michael R. Jirousek, Andrew J. Nichols. CAT‐2003: A novel sterol regulatory element‐binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3‐Leiden mice. Hepatology Communications 2017; 1(4) doi: 10.1002/hep4.1042
120
Ivica Grgurevic, Tonci Bozin, Mislav Mikus, Michal Kukla, James O’Beirne. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers 2021; 13(22) doi: 10.3390/cancers13225844
121
Matthew Kappus, Manal Abdelmalek. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017; 21(2) doi: 10.1016/j.cld.2016.12.006
122
Martti Färkkilä, Hannu Kautiainen, Andrea Tenca, Kalle Jokelainen, Johanna Arola, Antonio De Vincentis. PNPLA3 allele frequency has no impact on biliary bile acid composition or disease course in patients with primary sclerosing cholangitis. PLOS ONE 2022; 17(12) doi: 10.1371/journal.pone.0277084
123
Rosa Lombardi, Roberta Forlano, Gabriele Maffi, Annalisa Cespiati, Felice Cinque, Daniela Bignamini, Paola Dongiovanni, Paolo Francione, Giordano Sigon, Jian Huang, Pinelopi Manousou, Flora Peyvandi, Armando Tripodi, Anna Ludovica Fracanzani. Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIII. Digestive and Liver Disease 2025; 57(8) doi: 10.1016/j.dld.2025.05.011
124
Long Zhang, Wei You, Hanze Zhang, Rui Peng, Qin Zhu, Aihua Yao, Xiangcheng Li, Yebin Zhou, Xuehao Wang, Liyong Pu, Jindao Wu. PNPLA3 polymorphisms (rs738409) and non‐alcoholic fatty liver disease risk and related phenotypes: a meta‐analysis. Journal of Gastroenterology and Hepatology 2015; 30(5) doi: 10.1111/jgh.12889
125
Grace Teskey, Nivedita Tiwari, Andrew J. Butcko, Amit Kumar, Anuradha Yadav, Yu-ming M. Huang, Christopher V. Kelly, James G. Granneman, James W. Perfield, Emilio P. Mottillo. Lipid droplet targeting of the lipase coactivator ABHD5 and the fatty liver disease-causing variant PNPLA3 I148M is required to promote liver steatosis. Journal of Biological Chemistry 2025; 301(2) doi: 10.1016/j.jbc.2025.108186
126
Marica Meroni, Paola Dongiovanni, Miriam Longo, Fabrizia Carli, Guido Baselli, Raffaela Rametta, Serena Pelusi, Sara Badiali, Marco Maggioni, Melania Gaggini, Anna Ludovica Fracanzani, Stefano Romeo, Stefano Gatti, Nicholas O. Davidson, Amalia Gastaldelli, Luca Valenti. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine 2020; 52 doi: 10.1016/j.ebiom.2020.102658
127
Tyler J Severson, Siddesh Besur, Herbert L Bonkovsky. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World Journal of Gastroenterology 2016; 22(29): 6742-6756 doi: 10.3748/wjg.v22.i29.6742
128
Keyur Patel, Nicholas A. Shackel. Current status of fibrosis markers. Current Opinion in Gastroenterology 2014; 30(3) doi: 10.1097/MOG.0000000000000059
129
Giuseppina Umano, Mariangela Martino, Nicola Santoro. The Association between Pediatric NAFLD and Common Genetic Variants. Children 2017; 4(6) doi: 10.3390/children4060049
130
Lorne J. Hofseth, Ainsley Weston, Curtis C. Harris. Holland‐Frei Cancer Medicine. 2022;  doi: 10.1002/9781119000822.hfcm023.pub2
131
Joseph A. Akambase, Jhon E. Prieto, Angelo Z. Mattos, Angelo A. Mattos, Enrique Carrera, Javier Díaz‐Ferrer, Patricia Gallardo, Andrea Curia, Esteban G. Ballerga, Cristiane V. Tovo, Domingo Balderramo, Jose D. Debes. Epidemiology and risk factors for histopathologic characteristics of non‐alcoholic fatty liver disease in South America. Alimentary Pharmacology & Therapeutics 2023; 58(5) doi: 10.1111/apt.17615
132
Zelin Tian, Chen Xu, Peijun Yang, Zhibin Lin, Wenlong Wu, Wenjie Zhang, Jian Ding, Rui Ding, Xuan Zhang, Kefeng Dou. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.984728
133
Alexander Yang, Emilio P. Mottillo. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochemical Journal 2020; 477(5) doi: 10.1042/BCJ20190468
134
Luca Valenti, Serena Pelusi. Non-Alcoholic Fatty Liver Disease. 2020;  doi: 10.1007/978-3-319-95828-6_7
135
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, Georgios Germanidis. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacological Research 2022; 181 doi: 10.1016/j.phrs.2022.106261
136
Eleonora Dileo, Francesca Saba, Mirko Parasiliti-Caprino, Chiara Rosso, Elisabetta Bugianesi. Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies. Nutrients 2025; 17(3) doi: 10.3390/nu17030477
137
Somaya Albhaisi, Arun J. Sanyal. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.665987
138
Joseph Asemota, Olubunmi Oladunjoye, Atinuke Babalola, Ugonna Nwosu, Po-Hong S Liu, Adeolu O Oladunjoye, Nelsy Castro-Webb, Rebecca A Miksad. Comparison of Hepatocellular Carcinoma in Hispanics and Non-Hispanics Patients. Cureus 2021;  doi: 10.7759/cureus.14884
139
Patrick Borel, Charles Desmarchelier. Genetic Variations Associated with Vitamin A Status and Vitamin A Bioavailability. Nutrients 2017; 9(3) doi: 10.3390/nu9030246
140
Ainura Amirkulova, Gulmira Derbissalina, Valeriy Benberin, Nasrulla Shanazarov, Gulshara Abildinova, Doskhan Kozhakhmet, Helena Katchman. Association between PNPLA3 and TM6SF2 gene polymorphisms and non-alcoholic fatty liver disease patients in Kazakhstan. Electronic Journal of General Medicine 2023; 20(6) doi: 10.29333/ejgm/13718
141
Olivier Govaere, Quentin M. Anstee. Encyclopedia of Cell Biology. 2023;  doi: 10.1016/B978-0-12-821618-7.00265-0
142
Giovanni Targher, Luca Valenti, Christopher D. Byrne. Metabolic Dysfunction–Associated Steatotic Liver Disease. New England Journal of Medicine 2025; 393(7) doi: 10.1056/NEJMra2412865
143
Mark T. Miedel, Mark E. Schurdak, Andrew M. Stern, Alejandro Soto-Gutierrez, Eric von Strobl, Jaideep Behari, D. Lansing Taylor. Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective. Seminars in Liver Disease 2025; 45(04) doi: 10.1055/a-2649-1560
144
Alice Marmugi, Céline Lukowicz, Frederic Lasserre, Alexandra Montagner, Arnaud Polizzi, Simon Ducheix, Adeline Goron, Laurence Gamet-Payrastre, Sabine Gerbal-Chaloin, Jean Marc Pascussi, Marthe Moldes, Thierry Pineau, Hervé Guillou, Laila Mselli-Lakhal. Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way. Toxicology and Applied Pharmacology 2016; 303 doi: 10.1016/j.taap.2016.05.006
145
Ludovico Abenavoli. Alcoholic Liver Disease: From Bench to Bedside. Reviews on Recent Clinical Trials 2019; 14(3) doi: 10.2174/157488711403190718125454
146
Georgiana-Emmanuela Gîlcă-Blanariu, Daniela Simona Budur, Dana Elena Mitrică, Elena Gologan, Oana Timofte, Gheorghe Gh Bălan, Vasile Andrei Olteanu, Gabriela Ștefănescu. Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease. Metabolites 2023; 13(11) doi: 10.3390/metabo13111115
147
Annalisa Cespiati, Felice Cinque, Marica Meroni, Rosa Lombardi, Paola Dongiovanni, Anna Ludovica Fracanzani. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. Biomedicines 2023; 11(2) doi: 10.3390/biomedicines11020586
148
Peter Saliba-Gustafsson, Jennifer Härdfeldt, Matteo Pedrelli, Paolo Parini. Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease. International Journal of Molecular Sciences 2025; 26(22) doi: 10.3390/ijms262210881
149
Azam Moslehi, Zeinab Hamidi-zad. Role of SREBPs in Liver Diseases: A Mini-review. Journal of Clinical and Translational Hepatology 2018; 6(3) doi: 10.14218/JCTH.2017.00061
150
Massimiliano Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion, Paolo Magni, Luca Valenti, Paola Dongiovanni. Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine 2016; 48(5) doi: 10.1080/07853890.2016.1188328
151
Wonseok Lee, You-Jin Choi, Hyuneui Park, Suwan Chae, Byung-Hoon Lee. Abnormal lipid metabolism in metabolic dysfunction-associated steatohepatitis (MASH). Toxicological Research 2026;  doi: 10.1007/s43188-026-00387-3
152
William S. Blaner. Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders. Pharmacology & Therapeutics 2019; 197 doi: 10.1016/j.pharmthera.2019.01.006
153
Luca Valenti, Elisabetta Bugianesi, Utpal Pajvani, Giovanni Targher. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International 2016; 36(11) doi: 10.1111/liv.13185
154
Luigi Boccuto, Andrew Mitz, Ludovico Abenavoli, Sara M. Sarasua, William Bennett, Curtis Rogers, Barbara DuPont, Katy Phelan. Phenotypic Variability in Phelan–McDermid Syndrome and Its Putative Link to Environmental Factors. Genes 2022; 13(3) doi: 10.3390/genes13030528
155
S Pillai, S Duvvuru, P Bhatnagar, W Foster, M Farmen, S Shankar, C Harris, E Bastyr, B Hoogwerf, A Haupt. The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro. The Pharmacogenomics Journal 2018; 18(3) doi: 10.1038/tpj.2017.45
156
Meng-Yuan Wu, Jian-Gao Fan. Gut microbiome and nonalcoholic fatty liver disease. Hepatobiliary & Pancreatic Diseases International 2023; 22(5) doi: 10.1016/j.hbpd.2023.06.006
157
Stefano Romeo, Arun Sanyal, Luca Valenti. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism 2020; 31(1) doi: 10.1016/j.cmet.2019.12.002
158
Federico Salomone, Justyna Godos, Shira Zelber‐Sagi. Natural antioxidants for non‐alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver International 2016; 36(1) doi: 10.1111/liv.12975
159
Hisamitsu Miyaaki, Kazuhiko Nakao. Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. Clinical Journal of Gastroenterology 2017; 10(3) doi: 10.1007/s12328-017-0732-5
160
Benedikt Rumpf, Jonas Santol, Anna E. Kern, Markus Ammann, Joel Probst, Ruth Baumgartner, Anna S. Jankoschek, Vanja Podrascanin, Florian Lehner, Felix X. Huber, David Pereyra, Gregor Ortmayr, Yawen Dong, Sophia Petschnak, Brigitte Wolf, Alice Assinger, Hubert Hackl, Stefan Gilg, Thomas Gruenberger, Patrick Starlinger. PNPLA3 polymorphism worsens chemotherapy associated liver injury and affects overall survival in colorectal cancer patients with liver metastasis undergoing hepatic resection. eBioMedicine 2025; 120 doi: 10.1016/j.ebiom.2025.105928
161
Paola Dongiovanni, Stefano Romeo, Luca Valenti. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. BioMed Research International 2015; 2015 doi: 10.1155/2015/460190
162
Ozlem Kutlu, Humeyra Nur Kaleli, Ebru Ozer. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology 2018; 2018 doi: 10.1155/2018/8543763
163
Shuhua Yuan, Hongxia Liu, Ding Yuan, Jing Xu, Yunzhi Chen, Xiao Xu, Fen Xu, Hua Liang. PNPLA3 I148M mediates the regulatory effect of NF‐kB on inflammation in PA‐treated HepG2 cells. Journal of Cellular and Molecular Medicine 2020; 24(2) doi: 10.1111/jcmm.14839
164
Paola Dongiovanni, Jussi Pihlajamaki, Stefano Romeo, Luca Valenti. Reply to “Statin treatment for non-alcoholic steatohepatitis”. Journal of Hepatology 2016; 64(1) doi: 10.1016/j.jhep.2015.09.023
165
Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, Agostino Di Ciaula. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. International Journal of Molecular Sciences 2024; 25(11) doi: 10.3390/ijms25115640
166
Vincenzo Ronca, Alessio Gerussi, Paul Collins, Alessandro Parente, Ye Htun Oo, Pietro Invernizzi. The liver as a central “hub” of the immune system: pathophysiological implications. Physiological Reviews 2025; 105(2) doi: 10.1152/physrev.00004.2023
167
Alice Emma Taliento, Marcello Dallio, Alessandro Federico, Daniele Prati, Luca Valenti. Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health 2019; 16(15) doi: 10.3390/ijerph16152755
168
Gertrude Arthur, Michael I. Adenawoola, Sally Wahba, Bentley S. Montgomery, Claire B. Wingfield, Zachary A. Kipp, Terry D. Hinds, David E. Stec. The Human PNPLA3I148M Polymorphism Alters the Renal Kinome and Transporters to Cause Hyperfiltration and Hypertension. FASEB BioAdvances 2026; 8(9) doi: 10.1096/fba.2026-00222
169
Jose Altamirano, Eric S. Orman, Ramon Bataller. Yamada' s Textbook of Gastroenterology. 2015;  doi: 10.1002/9781118512074.ch103
170
Hisamitsu Miyaaki, Satoshi Miuma, Naota Taura, Hidetaka Shibata, Ryu Sasaki, Akihiko Soyama, Masaaki Hidaka, Mitsuhisa Takatsuki, Susumu Eguchi, Kazuhiko Nakao. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation. Transplantation 2019; 103(1) doi: 10.1097/TP.0000000000002319
171
Paola Dongiovanni, Marica Meroni, Miriam Longo, Silvia Fargion, Anna Ludovica Fracanzani. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021; 9(11) doi: 10.3390/biomedicines9111524
172
Felice Cinque, Annalisa Cespiati, Rosa Lombardi, Andrea Costantino, Gabriele Maffi, Francesca Alletto, Lucia Colavolpe, Paolo Francione, Giovanna Oberti, Erika Fatta, Cristina Bertelli, Giordano Sigon, Paola Dongiovanni, Maurizio Vecchi, Silvia Fargion, Anna Ludovica Fracanzani. Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients 2022; 14(3) doi: 10.3390/nu14030556
173
Haider Ghazanfar, Nismat Javed, Abeer Qasim, George Sarin Zacharia, Ali Ghazanfar, Abhilasha Jyala, Elona Shehi, Harish Patel. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. Cancers 2024; 16(6) doi: 10.3390/cancers16061214
174
Luigi Boccuto, Ludovico Abenavoli. The impact of genetic polymorphisms on liver diseases: entering the era of personalized medicine. European Journal of Gastroenterology & Hepatology 2017; 29(9) doi: 10.1097/MEG.0000000000000917
175
Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa. Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. World Journal of Clinical Pediatrics 2022; 11(3): 221-238 doi: 10.5409/wjcp.v11.i3.221
176
Eriks Smagris, Soumik BasuRay, John Li, Yongcheng Huang, Ka‐man V. Lai, Jesper Gromada, Jonathan C. Cohen, Helen H. Hobbs. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015; 61(1) doi: 10.1002/hep.27242
177
Yuli Sun, Zhaofeng Tan, Zhenyuan Jiang, Min Li, Weiqin Wang, Yaoyao Huang, Jianguang Sun. Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence. Medicine 2021; 100(3) doi: 10.1097/MD.0000000000024277
178
P. Wainwright, E. Scorletti, C. D. Byrne. Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. Current Diabetes Reports 2017; 17(4) doi: 10.1007/s11892-017-0851-x
179
Michael Karin, Ju Youn Kim. Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. Pharmacological Reviews 2025; 77(6) doi: 10.1016/j.pharmr.2025.100096
180
Francesca Lanzaro, Stefano Guarino, Elisabetta D'Addio, Alessandra Salvatori, Josè Alberto D'Anna, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa. Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions. World Journal of Hepatology 2022; 14(6): 1087-1098 doi: 10.4254/wjh.v14.i6.1087
181
Milla-M. Tauriainen, Maria A. Lankinen, Juhana M. Hakumäki, Olli M. Lahtinen, Minna Husso, Jyrki J. Ågren, Markku Laakso, Ursula S. Schwab. Patatin-like phosphatase domain-containing 3 genotype and quality of dietary fat modify the liver adiposity in men. European Journal of Nutrition 2026; 65(5) doi: 10.1007/s00394-026-04031-6
182
Pierre Bedossa, Keyur Patel. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology 2016; 150(8) doi: 10.1053/j.gastro.2016.03.008
183
Luigi Boccuto, Ludovico Abenavoli. Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. Annals of Hepatology 2017; 16(4) doi: 10.5604/01.3001.0010.0274
184
Claudia Maccali, Isabel V. A. Pereira, José Tadeu Stefano, Claudia P. Oliveira. Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores. Current Hepatology Reports 2023; 22(4) doi: 10.1007/s11901-023-00623-6
185
Ignacio Novo-Veleiro, Lucía Alvela-Suárez, Antonio-Javier Chamorro, Rogelio González-Sarmiento, Francisco-Javier Laso, Miguel Marcos. Alcoholic liver disease and hepatitis C virus infection. World Journal of Gastroenterology 2016; 22(4): 1411-1420 doi: 10.3748/wjg.v22.i4.1411
186
Bubu A. Banini, Divya P. Kumar, Sophie Cazanave, Mulugeta Seneshaw, Faridoddin Mirshahi, Prasanna K. Santhekadur, Liangsu Wang, Hong Ping Guan, Abdul M. Oseini, Cristina Alonso, Pierre Bedossa, Srinivas V. Koduru, Hae‐Ki Min, Arun J. Sanyal. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis. Hepatology 2021; 73(4) doi: 10.1002/hep.31609
187
Alexander Yang, Emilio P. Mottillo, Ljiljana Mladenovic-Lucas, Li Zhou, James G. Granneman. Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nature Metabolism 2019; 1(5) doi: 10.1038/s42255-019-0066-3
188
Pierluigi Marzuillo, Anna Grandone, Laura Perrone, Emanuele Miraglia del Giudice. Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics. World Journal of Hepatology 2015; 7(11): 1439-1443 doi: 10.4254/wjh.v7.i11.1439
189
Sean W.P. Koppe. Obesity and the liver: nonalcoholic fatty liver disease. Translational Research 2014; 164(4) doi: 10.1016/j.trsl.2014.06.008
190
Fernanda G. Arriaga-González, Felipe de Jesús Castañeda-Córdova, Mauricio Díaz-Muñoz, Matthew Hoare, David J. Adams, Carla Daniela Robles-Espinoza, Christian Molina-Aguilar. Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes. BMC Medical Genomics 2026; 19(1) doi: 10.1186/s12920-026-02332-7
191
Rosa Lombardi, Lucia Colavolpe, Francesca Alletto, Annalisa Cespiati, Erika Fatta, Cristina Bertelli, Felice Cinque, Giuseppina Pisano, Edoardo Pulixi, Paolo Francione, Gabriele Maffi, Federica Iuculano, Paola Dongiovanni, Marica Meroni, Larry Burdick, Daniela Bignamini, Marco Maggioni, Luca Valenti, Silvia Fargion, Anna Ludovica Fracanzani. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades. Digestive and Liver Disease 2024; 56(1) doi: 10.1016/j.dld.2023.07.009
192
Rosellina Margherita Mancina, Rocco Spagnuolo, Marta Milano, Simona Brogneri, Attilio Morrone, Cristina Cosco, Veronica Lazzaro, Cristina Russo, Yvelise Ferro, Piero Pingitore, Arturo Pujia, Tiziana Montalcini, Patrizia Doldo, Pietro Garieri, Luca Piodi, Flavio Caprioli, Luca Valenti, Stefano Romeo. PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. Inflammatory Bowel Diseases 2016; 22(1) doi: 10.1097/MIB.0000000000000569
193
Vittoria Moretti, Stefano Romeo, Luca Valenti. The contribution of genetics and epigenetics to MAFLD susceptibility. Hepatology International 2024; 18(S2) doi: 10.1007/s12072-024-10667-5
194
Lorne J. Hofseth, Ainsley Weston, Curtis C. Harris. Holland‐Frei Cancer Medicine. 2017;  doi: 10.1002/9781119000822.hfcm023
195
. 2022;  doi: 10.70675/9d9521bazf006z45a9z99e7z46894f7d43c4
196
Hyeyoung Kim, Kwang‐Woong Lee, Kyoungbun Lee, Sooin Seo, Min‐Young Park, Sung Woo Ahn, Suk Kyun Hong, Kyung Chul Yoon, Hyo‐Sin Kim, YoungRok Choi, Hae Won Lee, Nam‐Joon Yi, Kyung‐Suk Suh. Effect of PNPLA3 I148M polymorphism on histologically proven non‐alcoholic fatty liver disease in liver transplant recipients. Hepatology Research 2018; 48(3) doi: 10.1111/hepr.12940
197
Luca Valenti, Stefano Romeo. Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. Journal of Hepatology 2016; 65(4) doi: 10.1016/j.jhep.2016.06.010
198
Sasanka Ramanadham, Tomader Ali, Jason W. Ashley, Robert N. Bone, William D. Hancock, Xiaoyong Lei. Calcium-independent phospholipases A2 and their roles in biological processes and diseases. Journal of Lipid Research 2015; 56(9) doi: 10.1194/jlr.R058701
199
Eleonora Scorletti, Annette L. West, Lokpal Bhatia, Samuel P. Hoile, Keith G. McCormick, Graham C. Burdge, Karen A. Lillycrop, Geraldine F. Clough, Philip C. Calder, Christopher D. Byrne. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. Journal of Hepatology 2015; 63(6) doi: 10.1016/j.jhep.2015.07.036
200
Rotonya M. Carr, Rexford S. Ahima. Pathophysiology of lipid droplet proteins in liver diseases. Experimental Cell Research 2016; 340(2) doi: 10.1016/j.yexcr.2015.10.021
201
Piero Pingitore, Stefano Romeo. The role of PNPLA3 in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019; 1864(6) doi: 10.1016/j.bbalip.2018.06.018
202
Luca Rinaldi, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Maria Vittoria Morone, Chiara Silvestri, Mauro Giordano, Teresa Salvatore, Ferdinando Carlo Sasso. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants 2021; 10(2) doi: 10.3390/antiox10020270
203
Annalisa Crudele, Nadia Panera, Maria Rita Braghini, Clara Balsano, Anna Alisi. The pharmacological treatment of nonalcoholic fatty liver disease in children. Expert Review of Clinical Pharmacology 2020; 13(11) doi: 10.1080/17512433.2020.1829468
204
Jun Luo, Zhongshan Lu, Zibiao Zhong, Meichen Pi, Yan Xiong, Ling Li, Ting Chen, Yiwen Chen, Cong-Yi Wang, Zhongzhong Liu, Qifa Ye. ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism. Free Radical Biology and Medicine 2024; 212 doi: 10.1016/j.freeradbiomed.2023.12.017
205
Yoshitaka Sakurai, Naoto Kubota, Toshimasa Yamauchi, Takashi Kadowaki. Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences 2021; 22(8) doi: 10.3390/ijms22084156
206
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, Ger H. Koek, Robim M. Rodrigues, Tamara Vanhaecke. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review. Liver International 2023; 43(5) doi: 10.1111/liv.15533
207
Jincheng Wang, Tao Qin, Jinyu Sun, Shiwu Li, Lihua Cao, Xiaojie Lu. Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1046497
208
Kalliopi Azariadis, Nikolaos K. Gatselis, Aggeliki Lyberopoulou, Pinelopi Arvaniti, Kalliopi Zachou, Stella Gabeta, George N. Dalekos. PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality. Journal of Translational Autoimmunity 2024; 9 doi: 10.1016/j.jtauto.2024.100243
209
Sara Arefhosseini, Mehrangiz Ebrahimi-Mameghani, Farzad Najafipour, Helda Tutunchi. Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1032361
210
Dorothy A. Kieffer, Valentina Medici. Wilson disease: At the crossroads between genetics and epigenetics—A review of the evidence. Liver Research 2017; 1(2) doi: 10.1016/j.livres.2017.08.003
211
Marica Meroni, Miriam Longo, Alice Rustichelli, Paola Dongiovanni. Nutrition and Genetics in NAFLD: The Perfect Binomium. International Journal of Molecular Sciences 2020; 21(8) doi: 10.3390/ijms21082986
212
Marica Meroni, Miriam Longo, Paola Dongiovanni. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020; 1(4) doi: 10.37349/emed.2020.00015
213
Luca Valenti, Paola Dongiovanni. Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology 2017; 66(4) doi: 10.1002/hep.29298
214
Salvatore Petta, Luca Valenti, Elisabetta Bugianesi, Giovanni Targher, Stefano Bellentani, Ferruccio Bonino, Ele Ferrannini, Carmela Loguercio, Amedeo Lonardo, Fabio Marra, Marcello Mancini, Luca Miele, Valerio Nobili, Gianluca Svegliati Baroni, Federico Alessandro, Stefano Ballestri, Maurizia Rossana Brunetto, Barbara Coco, Antonio Grieco, Silvia Fargion, Loreta Kondili, Fabio Nascimbeni, Anna Prinster, Dante Romagnoli, Stefano Taddei, Ester Vanni, Stefano Vella. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016; 48(3) doi: 10.1016/j.dld.2015.10.027
215
Michele Nardolillo, Fabiola Rescigno, Mario Bartiromo, Dario Piatto, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. World Journal of Gastroenterology 2024; 30(15): 2081-2086 doi: 10.3748/wjg.v30.i15.2081
216
Mirella Pastore, Alessandra Gentilini, Fabio Marra. Non-Alcoholic Fatty Liver Disease. 2020;  doi: 10.1007/978-3-319-95828-6_6
217
Rotonya M. Carr, Jason Correnti. Insulin resistance in clinical and experimental alcoholic liver disease. Annals of the New York Academy of Sciences 2015; 1353(1) doi: 10.1111/nyas.12787
218
Hilmar K Lückhoff, Frederik C Kruger, Maritha J Kotze. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World Journal of Hepatology 2015; 7(9): 1192-1208 doi: 10.4254/wjh.v7.i9.1192
219
Paola Dongiovanni, Luca Valenti. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2017; 18(7) doi: 10.3390/ijms18071534
220
Stephen A. Harrison. Nonalcoholic Fatty Liver Disease and Fibrosis Progression: The Good, the Bad, and the Unknown. Clinical Gastroenterology and Hepatology 2015; 13(4) doi: 10.1016/j.cgh.2014.11.024
221
Pierre Bedossa, David E. Kleiner. Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016;  doi: 10.1007/978-3-319-20538-0_12
222
Joost Willebrords, Isabel Veloso Alves Pereira, Michaël Maes, Sara Crespo Yanguas, Isabelle Colle, Bert Van Den Bossche, Tereza Cristina Da Silva, Cláudia Pinto Marques Souza de Oliveira, Wellington Andraus, Venâncio Avancini Alves, Bruno Cogliati, Mathieu Vinken. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in Lipid Research 2015; 59 doi: 10.1016/j.plipres.2015.05.002
223
. 2019;  doi: 10.70675/22efc884z2788z43fazabc1zaeb115ea6833
224
Alison Mondul, Rosellina M Mancina, Andrea Merlo, Paola Dongiovanni, Raffaela Rametta, Tiziana Montalcini, Luca Valenti, Demetrius Albanes, Stefano Romeo. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. The Journal of Nutrition 2015; 145(8) doi: 10.3945/jn.115.210633
225
Carolyn Vespoli, Anoop Mohamed Iqbal, Mohammad Nasser Kabbany, Kadakkal Radhakrishnan. Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence. Endocrinology and Metabolism Clinics of North America 2023; 52(3) doi: 10.1016/j.ecl.2023.02.001
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.